Novartis Rejoins Protein Degradation Space with US$1.3 B Dunad Deal

By Lucy Haggerty

Pharma Deals Review: Vol 2021 Issue 11 (Table of Contents)

Published: 8 Nov-2021

DOI: 10.3833/pdr.v2021.i11.2644     ISSN: 1756-7874

Section: Research & Development



Jump starting its presence in protein degradation therapies, Novartis has entered into a strategic research collaboration with Dunad Therapeutics to develop oral covalent and protein degrading small molecule drugs for up to four undisclosed targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details